Cost utility analysis of deferasiroxversus deferoxamine for patients requiring iron chelation therapy in the United Kingdom

被引：0
作者：
Karnon, J.
Akehurst, R. L.
Jewitt, K.
Ossa, D.
机构：
[1] Univ Sheffield, Sheffield, S Yorkshire, England
[2] Novartis Plc, Camberley, England
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0598
引用
收藏
页码：222 / 223
页数：2
相关论文
共 50 条
  • [41] Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
    Taher, Ali T.
    Porter, John B.
    Kattamis, Antonis
    Viprakasit, Vip
    Cappellini, M. Domenica
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 7073 - 7075
  • [42] THE ROLE OF STRUCTURAL SENSITIVITY ANALYSIS IN THE MODELLING OF COST-EFFECTIVENESS (COST-UTILITY) IN PARKINSON'S DISEASE IN THE UNITED STATES AND UNITED KINGDOM
    Ratcliffe, A. E.
    VALUE IN HEALTH, 2012, 15 (04) : A145 - A145
  • [43] Clinical and economic burden of infused iron chelation therapy in the United States
    Payne, Krista A.
    Desrosiers, Marie-Pierre
    Caro, J. Jaime
    Baladi, Jean-Francois
    Lordan, Noreen
    Proskorovsky, Irina
    Ishak, Khajak
    Rofail, Diana
    TRANSFUSION, 2007, 47 (10) : 1820 - 1829
  • [44] IRON (FE) AND ALUMINUM (AL) CHELATION KINETICS DURING EXTENDED DEFEROXAMINE (DFO) THERAPY (RX) IN FE LOADED HEMODIALYSIS (HD) PATIENTS
    STIVELMAN, J
    HAKIM, R
    SCHULMAN, G
    FOSBURG, M
    LAZARUS, JM
    KIDNEY INTERNATIONAL, 1986, 29 (01) : 226 - 226
  • [45] The cost-utility of exelon patch in the management of patients with moderate Alzheimer's disease in the United Kingdom
    Brennan, A.
    Nagy, B.
    Brandtmuller, A.
    Thomas, S. K.
    Sullivan, S. D.
    Akehurst, R.
    VALUE IN HEALTH, 2007, 10 (06) : A384 - A384
  • [46] TOCILIZUMAB IN METHOTREXATE-INTOLERANT OR CONTRAINDICATED PATIENTS-A COST-UTILITY MODEL FOR THE UNITED KINGDOM
    Harland, Dave
    Gibbons, Carl
    Pang, Hok
    Huertas, Catherine
    Diamantopoulos, Alex
    Dejonckheere, Fred
    RHEUMATOLOGY, 2013, 52 : 84 - 84
  • [47] Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes
    Kontoghiorghe, Christina N.
    Kontoghiorghes, George J.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 465 - 481
  • [48] Iron chelation therapy for patients with sickle cell disease and iron overload
    Inati, Adlette
    Khoriaty, Evelyne
    Musallam, Khaled M.
    Taher, Ali T.
    AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (10) : 782 - 786
  • [49] Cost-utility analysis of normothermic liver perfusion with the OrganOxmetracompared to static cold storage in the United Kingdom
    Javanbakht, Mehdi
    Mashayekhi, Atefeh
    Trevor, Miranda
    Branagan-Harris, Michael
    Atkinson, Jowan
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (11) : 1284 - 1292
  • [50] Treatment with hydroxyurea and iron chelation therapy in patients with hemoglobinopathies
    Maggio, A
    Rigano, P
    D'Amico, G
    Mascolino, A
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2005, 75 (03) : 267 - 269
12345